Spinal muscular atrophy: an integrated medical and pharmacy claims analysis of nusinersen uptake and gene therapy forecast among 15 million commercially insured
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.